Benzylideneacetophenone derivatives attenuate IFN-γ-induced IP-10/CXCL10 production in orbital fibroblasts of patients with thyroid-associated ophthalmopathy through STAT-1 inhibition

Experimental and Molecular Medicine

Volumn 46, Issue 6, 2014, Pages

  Lee, Sung Hee ^a   Lim, Seul Ye ^a   Choi, Ji Ha ^a   Jung, Jae Chul ^a   Oh, Seikwan ^a   Kook, Koung Hoon ^b   Choi, Youn Hee ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Benzylideneacetophenone; CXCL10 ip 10; IFN ; Orbital fibroblasts; Thyroid associated ophthalmopathy; Yakuchinone B

Indexed keywords

CHALCONE DERIVATIVE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; STAT PROTEIN; UNCLASSIFIED DRUG; YAKUCHINONE B; [3 (4 HYDROXY 3 METHOXYPHENYL)PHENYLPRO 2 EN L ONE]; CHALCONE; CXCL10 PROTEIN, HUMAN; HEPTANE DERIVATIVE; MESSENGER RNA; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG STRUCTURE; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; GENETICS; METABOLISM; ORBIT; SYNTHESIS;

CELLS, CULTURED; CHALCONE; CHEMOKINE CXCL10; DIARYLHEPTANOIDS; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; INTERFERON-GAMMA; ORBIT; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR;

EID: 84902145200     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.26     Document Type: Article

References (38)

1. Pappa A, Lawson JM, Calder V, Fells P, Lightman S. T cells and fibroblasts in affected extraocular muscles in early and late thyroid-associated ophthalmopathy. Br J Ophthalmol 2000; 84: 517-522.
2. Eckstein AK, Quadbeck B, Tews S, Mann K, Kruger C, Mohr CH et al. Thyroid-associated ophthalmopathy: evidence for CD4() gammadelta T cells; de novo differentiation of RFD7() macrophages, but not of RFD1() dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression. Br J Ophthalmol 2004; 88: 803-808.
3. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000; 85: 1194-1199.
4. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSHR expression and cytokine profile in orbital tissue of active vs inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 2003; 58: 280-287.
5. Bahn RS. Graves' ophthalmopathy. New Engl J Med 2010; 362: 726-738.
6. Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 2005; 175: 1310-1319.
7. Han R, Tsui S, Smith TJ. Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem 2002; 277: 16355-16364.
8. Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1 and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol, 2002; 32: 477-485.
9. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985; 315: 672-676.
10. Clarke DL, Clifford RL, Jindarat S, Proud D, Pang L, Belvisi M et al. TNFalpha and IFNgamma synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-kappaB, and the transcriptional coactivator CREB-binding protein. J Biol Chem 2010; 285: 29101-29110.
11. Kim HJ, Song DE, Lim SY, Lee SH, Kang JL, Lee SJ et al. Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes. PLoS One 2011; 6: e26264.
12. Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010; 50: 1-14.
13. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM et al. Interferon (IFN)-gamma-inducible protein-10: Association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
14. Syed Ahamed Kabeer B, Paramasivam P, Raja A. Interferon gamma and interferon gamma inducible protein-10 in detecting tuberculosis infection. J Infect 2012; 64: 573-579.
15. Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S et al. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 2005; 174: 5324-5331.
16. Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123: 271-279.
17. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3 lymphocytes. J Clin Endocrinol Metab 2001; 86: 5008-5016.
18. Rotondi M, Chiovato L. The chemokine system as a therapeutic target in autoimmune thyroid diseases: A focus on the interferon-gamma inducible chemokines and their receptor. Curr Pharm Des 2011; 17: 3202-3216.
19. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006; 91: 614-620.
20. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: A short review. Food Chem Toxicol 2002; 40: 1091-1097.
21. Srimal RC, Sharma JN, Tangri AN, Dhawan BN. Experimental evaluation of anti-inflammatory activity of 3, 4-dimethoxyphenylethylamino-3-aminopyridine (Compound 64-92). Indian J Exp Biol 1973; 11: 183-187.
22. Chun KS, Sohn Y, Kim HS, Kim OH, Park KK, Lee JM et al. Anti-tumor promoting potential of naturally occurring diarylheptanoids structurally related to curcumin. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999; 428: 49-57.
23. Ninomiya Y, Shimma N, Ishitsuka H. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides. Antiviral Res 1990; 13: 61-74.
24. Oh S, Jang S, Kim D, Han IO, Jung JC. Synthesis and evaluation of biological properties of benzylideneacetophenone derivatives. Arch Pharm Res 2006; 29: 469-475.
25. Kim H, Choi YH, Park SJ, Lee SY, Kim SJ, Jou I et al. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci 2010; 51: 3061-3066.
26. Zhao LQ, Wei RL, Cheng JW, Cai JP, Li Y. The Expression of Intercellular Adhesion Molecule-1 Induced by CD40-CD40L Ligand Signaling in Orbital Fibroblasts in Patients with Graves' Ophthalmopathy. Invest Ophthalmol Vis Sci 2010; 51: 4652.
27. Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid- Associated ophthalmopathy. Thyroid 2002; 12: 197-203.
28. Epstein FH, Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Eng J Med 1993; 329: 1468-1475.
29. Khoo TK, Bahn RS. Pathogenesis of Graves' ophthalmopathy: The role of autoantibodies. Thyroid 2007; 17: 1013-1018.
30. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747-793.
31. Kiuchi F, Iwakami S, Shibuya M, Hanaoka F, Sankawa U. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem Pharm Bull (Tokyo) 1992; 40: 387-391.
32. Surh YJ, Park KK, Chun KS, Lee LJ, Lee E, Lee SS. Anti-tumor-promoting activities of selected pungent phenolic substances present in ginger. J Environ Pathol Toxicol Oncol 1999; 18: 131-139.
33. Jang S, Jung JC, Kim DH, Ryu JH, Lee Y, Jung M et al. The neuroprotective effects of benzylideneacetophenone derivatives on excitotoxicity and inflammation via phosphorylated Janus tyrosine kinase 2/phosphorylated signal transducer and activator of transcription 3 and mitogenactivated protein K pathways. J Pharmacol Exp Ther 2009; 328: 435-447.
34. Kang JM, Jung JC, Kim H, Lim H, Jang S, Oh S. Neuroprotective effect of benzylideneacetophenone derivative on the MPTP model of neurodegeneration in mice. Arch Pharm Res 2008; 31: 1098-1107.
35. Spurrell JC, Wiehler S, Zaheer RS, Sanders SP, Proud D. Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell Mol Physiol 2005; 289: L85-L95.
36. Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab 2012; 26: 291-302.
37. Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy: The role of the TSH receptor. Best Pract Res Clin Endocrinol Metab 2012; 26: 281-289.
38. Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 2011; 22: 385-390.